Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- United States
- United Kingdom
- Canada
- Switzerland
- Israel
- Germany
- Netherlands
Investment stages
- Seed
- Series A
- Series B
- Series C
- Growth
Industries
- Artificial Intelligence
- Machine Learning
- Biotechnology
- Life Sciences
- Drug Discovery
- Advanced Manufacturing
- Computational Biology
- TechBio
- Deep Tech
- Enterprise Software
- Healthcare
About
Dimension is a New York-based venture capital firm focused on backing companies at the intersection of biotechnology and computing. Their focus spans AI, machine learning, life sciences, biotech, and drug discovery across the United States, United Kingdom, Canada, Switzerland, Israel, Germany, and Netherlands. The firm supports frontier tech founders from seed through growth stages.
Dimension is a New York-based venture capital firm focused on backing companies at the intersection of biotechnology and computing. Their focus spans AI, machine learning, life sciences, biotech, and drug discovery across the United States, United Kingdom, Canada, Switzerland, Israel, Germany, and Netherlands. The firm supports frontier tech founders from seed through growth stages.
Investment Thesis
Dimension is a seed to growth stage multistage venture capital firm deploying capital across artificial intelligence, machine learning, biotechnology, life sciences, drug discovery, advanced manufacturing, and computational biology sectors. They invest as high-conviction lead investors with concentrated positions (roughly 20 per fund) in companies at the frontiers of science and compute, working closely with founders as core architects. The firm differentiates itself through research-oriented approach led by former Lux Capital and Obvious Ventures partners, with $850M AUM across two funds and unique technical-life sciences bridging capabilities.
Manager's Experience
Founded in 2023 by Zavain Dar and Adam Goulburn (both former General Partners at Lux Capital) and Nan Li (former Managing Director at Obvious Ventures). Team of 9 including 4 partners across New York and San Francisco. Manages $1.65B AUM across three funds: Fund I ($350M, 2022), Fund II ($500M oversubscribed 2024), Fund III ($800M closed 2026). Portfolio includes Chai Discovery ($3.8B), Enveda Biosciences, New Limit, Monte Rosa (public), and Coefficient Bio (acquired by Anthropic for $400M).
Team
Zavain Dar - Co-founder & Managing Partner
Adam Goulburn - Co-founder & Managing Partner
Nan Li - Co-founder & Managing Partner
Nikhil Namburi - Investment Team
Rami Hathwar - Investment Team
Simon Barnett - Research
Bauer LeSavage - Research
Frank Gao - Research
Anna Bitton - Operations
Alana Green - Operations
Amy Zhen - Operations
AnneMarie Bott - Operations
Portfolio
Chai Discovery
Enveda Biosciences
Monte Rosa Therapeutics
New Limit
Coefficient Bio
Congruence Therapeutics
Earendil Labs
Kaleidoscope Bio
Sensorion
Stealth BioTherapeutics
Harvey